Fiche publication
Date publication
mars 2023
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Matte P, Bihan K, Isnard-Bagnis C, Zahr N, Thiery-Vuillemin A, Gougis P, Campedel L
Lien Pubmed
Résumé
The number of cancer patients receiving long-term hemodialysis (HD) is increasing, and HD could jeopardize treatments' safety and efficacy. Therefore, managing anticancer drugs is critical in this frail population. In addition, evidence of HD safety or risk is regularly released both for cytotoxic chemotherapy (CT) or hormone therapy (HT) as well as new therapies with molecularly targeted therapies (MTT), immune checkpoint inhibitors (ICI), and a summary of current knowledge is needed.
Mots clés
Chemotherapy, Hemodialysis, Hormone therapy, Immunotherapy, Renal insufficiency, Targeted therapy
Référence
Bull Cancer. 2023 03 15;:
